Wolverine Blend
BPC-157 + TB-500 healing blend
Wolverine Blend (BPC-157 + TB-500 healing blend) is a blends & other research compound. The soft-tissue repair blend — BPC-157 and TB-500 in one draw. BPC-157 drives angiogenesis, tendon/ligament fibroblast migration and gut/vascular repair; TB-500 (the active fragment of thymosin beta-4) sequesters actin to accelerate cell migration and systemic recovery. Together they hit both the local and systemic arms of tissue healing.
Wolverine Blend quick facts
| Reported research dose | 200-600mcg BPC,TB |
| Route | Subq |
| Frequency | 1x Daily · 5 On 2 Off or Daily |
| Half-life | Mixed (BPC short · TB days) |
| Forms | Injectable |
| Evidence level | Anecdotal (blend) |
The 'Wolverine' healing stack — one shot instead of two draws. Mixed evenly, usually 5/5mg or 10/10mg per vial.
How Wolverine Blend works
The soft-tissue repair blend — BPC-157 and TB-500 in one draw. BPC-157 drives angiogenesis, tendon/ligament fibroblast migration and gut/vascular repair; TB-500 (the active fragment of thymosin beta-4) sequesters actin to accelerate cell migration and systemic recovery. Together they hit both the local and systemic arms of tissue healing.
Proposed benefits
A combination formula — proposed benefits reflect the sum of its individual components.
Where to get Wolverine Blend
Wolverine Blend is sold in 3 forms. They are not interchangeable — the dose and the route differ, so pick the one this page describes unless you know why you want another.
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Wolverine Blend
Graded by what exists behind each claim.
✅ Clinically validated
- No trial of the blend. It combines BPC-157 and TB-500 — the two most-used repair peptides — so its evidence is theirs. See each component's clinical tier, both of which are honest about the absence of completed human trials.
📊 Correlative data
- The most common repair pairing in the research space, sold pre-combined for convenience. Reported experience is what you would expect from running both separately.
🧪 Theoretical / extrapolated
- Two complementary repair mechanisms: BPC-157 drives angiogenesis at the injury site, TB-500 drives the migration of repair cells into it. Blood supply and cell delivery are different halves of the same job, which is the mechanistic case for pairing them and the reason this blend exists rather than a double dose of either.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Wolverine Blend actually does
This is two peptides in one vial, and the interesting question is not what each does — it is what putting them in a fixed ratio costs.
The two mechanisms are genuinely complementary, which is why the pairing exists. BPC-157 is a pentadecapeptide derived from a sequence in human gastric juice; the literature around it is a cytoprotection literature, describing recovery of a severed myotendinous junction and simultaneous healing of transected tendon, muscle, ligament and bone in rat injury models, given intraperitoneally, in drinking water or topically at the injury site Staresinic 2022. TB-500 is the LKKTETQ heptapeptide corresponding to the actin-binding motif of thymosin beta-4, and its mechanism is actin sequestration — freeing the cytoskeletal machinery that lets repair cells migrate into a wound Zoubek 2007.
Blood supply and cell delivery are different halves of one job, and that is a real mechanistic argument for combining them. A wound with new vessels and no migrating fibroblasts does not close; neither does one with migrating cells and no perfusion. Nothing on this page disputes that the pairing is sensible in principle.
What the fragment is and is not. Thymosin beta-4 is a 43-residue protein; TB-500 is seven of those residues. Work defining the biological activities of thymosin beta-4 by mapping them onto short peptide sequences found that different activities localize to different regions of the protein Sosne 2010, and the actin-binding motif's contribution has been separated from the N-terminal region experimentally Zoubek 2007. So the heptapeptide is one function of the parent protein, not a smaller version of all of them — and the human trials in this area used the intact protein Wang 2021Guarnera 2007, not the fragment.
The mechanistic problem with a fixed ratio is kinetic, not pharmacodynamic. The card's own half-life field says it: BPC short, TB days. Two molecules with clearance rates an order of magnitude apart, mixed in one syringe and injected on one schedule, cannot both be dosed correctly. Whichever schedule suits one is wrong for the other, and the vial makes that choice for you before you open it.
Cell, rodent, human — and where it stops
Step one, cells and biochemistry. The actin-sequestering activity of the thymosin beta-4 motif is measurable in vitro, and the influence of the N-terminus and the actin-binding motif on that interaction has been dissected directly Zoubek 2007. Activities of the parent protein have been assigned to specific short sequences within it Sosne 2010.
Step two, rodents. The BPC-157 literature is almost entirely a rat literature, and it is broad: myotendinous junction, tendon, muscle, ligament and bone, with the peptide given intraperitoneally, in drinking water, or applied topically to the injury Staresinic 2022. Thymosin beta-4 and a synthetic peptide containing its actin-binding domain both promoted dermal healing in animal work Philp 2003.
Step three, humans — and the two halves of this blend are in completely different places. Thymosin beta-4 has been into people: a European prospective randomized study in venous ulcers Guarnera 2007 and a first-in-human randomized, double-blind, single- and multiple-dose phase 1 study of the recombinant protein Wang 2021. BPC-157 has no completed randomized human efficacy trial for any musculoskeletal indication, and TB-500 — the seven-residue fragment actually in this vial — has none either. The human work belongs to the intact 43-residue protein, which is a different molecule from the one being injected.
The obstacle, stated as an arithmetic problem rather than a shrug. Suppose the blend is mixed 1:1 and injected daily, and take the card's own characterization at face value: one component cleared in hours, the other with a multi-day residence. A compound with a two-day half-life dosed once daily accumulates to roughly 3.4 times its single-dose exposure at steady state; with a three-day half-life the factor is about 4.8. The short component does not accumulate at all — each injection is a fresh pulse from zero. So after three weeks of daily dosing the ratio in the body is nothing like the ratio in the vial, and nobody selling a fixed blend publishes the number.
And the second obstacle, which is that no trial has ever tested the combination. Every result above is one peptide at a time. A blend inherits its components' evidence only if the components do not interact, and that is an assumption, not a finding.
Wolverine Blend pharmacokinetics — how much of it actually gets in
The card says ‘Mixed’, which is honest and is also the whole difficulty. Here is what mixed actually means in numbers.
What degrades each half. Both are linear peptides with free termini and no protective modification — no D-amino acids, no cyclization, no fatty-acid anchor — so both are substrates for serum and tissue aminopeptidases and endopeptidases. The heptapeptide is the more exposed of the two simply because a shorter peptide presents fewer residues between one terminus and the other. Neither is a cytochrome substrate; neither has a meaningful hepatic metabolism story; proteolysis is the whole clearance route.
The oral barrier, and why one component has an argument the other does not. Oral bioavailability for both is poor for the usual reasons — gastric pepsin, pancreatic proteases, brush-border aminopeptidases, then first-pass hepatic extraction. The asymmetry is that the BPC-157 literature explicitly includes oral and in-drinking-water administration in rats and reports effects from it Staresinic 2022, which is a claim about local gut action rather than about systemic exposure. There is no equivalent claim for the thymosin fragment, so an oral version of this blend is at best half a product.
The subcutaneous arithmetic that decides the schedule. Reaching steady state takes about 4 to 5 half-lives. For the slow component that is 8 to 15 days of daily injections before exposure stops rising; for the fast component steady state is reached and lost again within a single day. The practical consequence: judging this blend at day 5 is judging one component at full exposure and the other at roughly half, and a dose adjustment made in the first week is being made against a moving number.
Reconstitution, which is a kinetics question in disguise. Two peptides in one vial share one diluent and one storage history. Peptide stability in bacteriostatic water is not identical across sequences, so the ratio drifts in the vial as well as in the body, and there is no assay a buyer can run to check either. That is a genuine argument for two separate draws over one convenient one — the opposite of the reason the blend exists.
What would have to be true, and how you would know it was not
Three predictions. The first two are cheap; the third is the one that would show the blend format is costing something.
1. hs-CRP should not rise, and a rise means the injection site rather than the injury. Neither component has a mechanism that predicts systemic inflammation. Prediction: hs-CRP at baseline and at 6 weeks is unchanged. A rise on a stable training load points at the depot — two peptides plus a preservative in one bolus — not at a healing response, and it is the fastest way to tell an irritated site from a working one.
2. A CMP and CBC should stay flat, and that is worth establishing precisely because the literature is silent. There is no published human safety dataset for either component at these doses over months. Prediction: CMP and CBC at baseline and 12 weeks show no drift in liver enzymes, creatinine or white count. This is not a mechanism-driven prediction; it is the baseline anybody self-experimenting owes themselves, and it is the only way an individual contributes anything checkable to a literature that has none.
3. Against the blend format: the same total dose given as two separate injections on two different schedules should outperform the fixed mix, and the test is a crossover on one person. The argument is the accumulation arithmetic above — daily dosing of a multi-day peptide reaches several times its single-dose exposure while the short one does not accumulate at all. Prediction: splitting the components, dosing the fast one daily and the slow one twice weekly at matched weekly totals, produces the same or better subjective recovery at a lower total peptide load. If it does not — if the fixed blend on one schedule is genuinely equivalent — then the kinetic mismatch does not matter in practice and this prediction is wrong. Either answer is information nobody currently has.
What nobody has tested yet
Four things nobody has measured about this specific product.
Whether the two peptides are stable together in one vial. Co-formulation is the entire selling point and there is no published stability study of this pair in bacteriostatic water at room temperature or refrigerated. Mass spectrometry on a reconstituted vial at day 1 and day 30 would answer it and has never been published for any blend on this site.
What the actual ratio in the body is at steady state. The calculation above is arithmetic from the card's own half-life description, not measurement. Two plasma samples on day 21 — one at trough, one two hours post-injection — would convert the estimate into a number.
Whether the heptapeptide reproduces any human result the intact protein produced. The human trials used thymosin beta-4 Wang 2021Guarnera 2007; activities of that protein map onto different short sequences Sosne 2010. Whether the actin-binding fragment alone does anything measurable in a person has not been tested in a controlled study.
Whether the pairing is additive, redundant or antagonistic. Angiogenesis and cell migration are sequential steps in the same process, and sequential steps are not automatically additive when driven simultaneously. A three-arm animal study — each peptide alone and both together, one injury model, one endpoint — is an ordinary experiment and it has not been published.
Wolverine Blend — its own safety story, not its class's
The specific risk of this product is not either peptide. It is the format.
A blend removes the ability to attribute anything. If something good happens, two candidates; if something bad happens, two candidates and a preservative. There is no titration path that moves one without moving the other, so a person who tolerates one component poorly has to abandon both. That is a real cost and it is the predictable consequence of a fixed ratio.
The honest statement about the safety literature. The BPC-157 review describes a very safe profile in animal work — a lethal dose was not achieved, across a wide effective range and multiple routes Staresinic 2022. That is an animal statement. It is not the same as a human safety dataset, and no long-term human safety dataset exists for either component of this blend.
The angiogenesis question, which applies to both halves. Both components act on processes — new vessel formation and cell migration — that a tumor also uses. Nothing in the published record demonstrates that either promotes tumor growth in a person, and nothing demonstrates that it does not, because the studies have not been done. The population where that matters is anyone with an active or recent malignancy, and the honest answer there is that the question is open rather than reassuring.
Sourcing, specific to a two-peptide vial. A blend is compounded by whoever filled it, and the buyer has no way to verify either identity, either quantity, or the ratio. A single-peptide vial at least fails in one dimension. This one can be wrong in three, and the ‘5/5 or 10/10 per vial’ that circulates is a claim about a label rather than a measurement.
Sources read for this page
- Staresinic M, et al. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines 2022 · PMID 36551977
- Sosne G, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB Journal 2010 · PMID 20179146
- Philp D, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration 2003 · PMID 12581423
- Wang X, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. Journal of Cellular and Molecular Medicine 2021 · PMID 34346165
- Guarnera G, et al. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Annals of the New York Academy of Sciences 2007 · PMID 17495250
- Zoubek RE, Hannappel E. Influence of the N terminus and the actin-binding motif of thymosin beta4 on its interaction with G-actin. Annals of the New York Academy of Sciences 2007 · PMID 17495251
Wolverine Blend — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- A BPC-157 and TB-500 combination under a brand name. No new mechanism — if you already run either peptide, this is the same thing repackaged.
- *the BPC-157 / TB-500 arms:* Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signaling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumor needs to grow beyond a few millimetres.
- *the BPC-157 / TB-500 arms:* There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- *the BPC-157 / TB-500 arms:* The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
- The risk that belongs to the blend rather than any component: double-dosing. If you already run any of the peptides above separately, adding this blend means two doses of it — and almost nobody counts a blend's arms against what is already in their protocol. Read the composition against your current stack before the first injection.
What has actually been reported
- *the BPC-157 / TB-500 arms:* Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- *the BPC-157 / TB-500 arms:* Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- *the BPC-157 / TB-500 arms:* Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- *the BPC-157 / TB-500 arms:* Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- *the BPC-157 / TB-500 arms:* Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- *the BPC-157 / TB-500 arms:* One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- *the BPC-157 / TB-500 arms:* Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- *the BPC-157 / TB-500 arms:* Active or recently treated malignancy — the angiogenesis reasoning.
- *the BPC-157 / TB-500 arms:* Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- *the BPC-157 / TB-500 arms:* Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Wolverine Blend — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Wolverine Blend moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
From the BPC-157 / TB-500 arm. If a repair peptide is doing anything systemic, inflammation is where it would plausibly show.
What to do: Worth a baseline if you are running one for a chronic issue rather than an acute injury. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
From the BPC-157 / TB-500 arm. Standard baseline. Nothing in this class predicts a specific abnormality — which is itself worth saying rather than inventing one.
What to do: Annual is fine unless something changes.
A BPC-157 and TB-500 combination under a brand name. Nothing here is a new mechanism — if you are already running either peptide, this is the same thing at a different price.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Wolverine Blend in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Wolverine Blend
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Comprehensive Metabolic Panel (CMP) | Liver, kidney, electrolytes and glucose in one |
| Complete Blood Count (CBC) with Differential | Broad screen for anything unexpected |
| hs-CRP (High-Sensitivity C-Reactive Protein) | Inflammation baseline |
The Basics — Start Here panel covers these in one order — 4 markers, $32.40 with the discount applied.
Check results you already have → · All 103 markers A–Z
Wolverine Blend — frequently asked questions
What is Wolverine Blend?
Wolverine Blend (BPC-157 + TB-500 healing blend) is a blends & other research compound. The soft-tissue repair blend — BPC-157 and TB-500 in one draw. BPC-157 drives angiogenesis, tendon/ligament fibroblast migration and gut/vascular repair; TB-500 (the active fragment of thymosin beta-4) sequesters actin to accelerate cell migration and systemic recovery. Together they hit both the local and systemic arms of tissue healing.
Is the full Wolverine Blend protocol on this page?
The reported research dose is on this page, along with how Wolverine Blend works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Wolverine Blend?
Wolverine Blend has an approximate half-life of Mixed (BPC short · TB days), which is part of what determines how often it's dosed.
What's the evidence behind Wolverine Blend?
Current evidence level: Anecdotal (blend). Wolverine Blend is offered for research purposes only and is not an approved medicine.
Wolverine Blend inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Wolverine Blend is used for
Wolverine Blend appears under 1 goal in the goal router.
Related Blends & Other compounds
Where this goes next
Wolverine Blend is the angiogenesis arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.